BRAIN Biotech : receives major milestone payment and stays on-track to achieve year end targets

• Major milestone payment from pharma-project of € 1.5 million received
• BioProducts business growth accelerated in Q2, further acceleration expected throughout H2
• On-track to meet fiscal year end targets
• Significantly strengthened cash position

BRAIN Biotech AG, a leading provider of integrated solutions for the biologization of industry, today published its half year results, 6M 2023/2024. BRAIN received a significant milestone payment of € 1.5 million in its second quarter for the successful development progress in the out-licensed active pharmaceutical ingredient program with deucrictibant (formerly PHA121). Overall cash on hand almost doubled to € 10.2 million compared to September 30, 2023. The company stays fully on track to meet its business year targets for FY 2023/24.

In the first six months of the 2023/2024 financial year, BRAIN Biotech Group generated revenues of € 27.2 million, which is at the same level as the previous year. In the second quarter of 2023/24, revenue increased by € 1.0 million or 7.4 % to € 14.5 million. Total operating performance decreased by 2.6 % from € 28.1 million to € 27.4 million in the first six months of the financial year. This was primarily due to negative changes in inventories and lower other income compared to the same period of the previous year. The adjusted Group EBITDA in the first half of the 2023/24 financial year improved by € 0.4 million from € -0.9 million in the previous year to € -0.5 million.

Adriaan Moelker, CEO of BRAIN Biotech AG says: "The significant € 1.5 million milestone payment from our licensee Pharvaris clearly demonstrates that we are starting to harvest the fruits of our past investments and that our BioIncubator pipeline increasingly creates value. We continue to aim for accelerated commercialization of our many BioIncubator projects." Moelker adds, "I am also very pleased that the growth in the BioProducts segment has accelerated in the second quarter as forecasted and I remain confident that the second half in our products business will be even stronger."

Development of segments

In the BioProducts segment, which comprises the product business with specialty enzymes and other proteins, revenues decreased by 5.0 % from € 20.9 million to € 19.8 million in the reporting period. Total operating performance amounted to € 19.7 million, down 6.5 % on the same quarter of the previous year. Revenues in the second quarter totaled € 10.5 million, an encouraging increase compared to € 9.3 million in the first quarter of the financial year. The cost of materials was reduced from € 11.5 million to € 10.2 million. This led to an improved cost of materials ratio compared to the same period of the previous year. Overall, the BioProducts segment's adjusted EBITDA fell from € 2.2 million to € 1.7 million, primarily due to the lower revenues.

The BioScience segment which includes research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening generated revenues of € 5.8 million in the reporting period, which corresponds to a decrease of 5.3 % compared to the same period of the previous year (€ 6.1 million). Thanks to stringent project controlling and good general cost control, the segment's adjusted EBITDA was maintained at the previous year's level of € 0.0 million.

Revenues of the BioIncubator segment, which covers revenues from own R&D projects or those initiated with partners increased significantly from € 0.2 million to € 1.6 million in the reporting period compared to the same period of the previous year. A large milestone in the deucrictibant project (PHA121) was successfully achieved in the reporting quarter, making a significant contribution to the growth in revenues. The strong revenue growth is also reflected in the segment's adjusted EBITDA, which improved from € -1.6 million in the previous year to € -0.5 million. Overall, the segment continues to be characterized by high investments of € 1.5 million in the area of genome editing under the brand name Akribion Genomics.

The BRAIN Biotech Holding segment mainly includes personnel expenses and other expenses for Group administration, further development of the BRAIN Biotech Group, stock exchange listing and M&A activities. The adjusted EBITDA of the segment amounted to € -1.7 million and was therefore only slightly below the previous year's level (€ -1.6 million).

The financial year guidance remains unchanged to achieve revenues in a range of € 58 - 62 million with an adjusted EBITDA to rise, at least, in-line with the revenue growth.

Key financials (first six months of the financial year 2023/24)

(in € million)	6M 2023/24	6M 2022/23
Revenues	27.2	27.2
BioProducts	19.8	20.9
BioScience	5.8	6.1
BioIncubator	1.6	0.2
Total operating performance1	27.4	28.1
Adjusted EBITDA2	-0.5	-0.9
EBITDA	-0.9	-1.3
Operating cash flow	-3.2	-5.6
31.03.2024	30.09.2023
Cash and cash equivalents	10.2	5.4

1 Revenues + change in inventories + other income including R&D grants

2 The reconciliation from adjusted to unadjusted EBITDA can be found in the 6M report for the period October 1, 2023 to March 31, 2024

Further information

BRAIN Biotech AG 6M Report 2023/24:
https://www.brain-biotech.com/investors/financial-news